Calypso Medical
Date | Investors | Amount | Round |
---|---|---|---|
$6.8m | Series C | ||
$42.2m | Series D | ||
N/A | $2.9m | Debt | |
$50.0m | Series E | ||
N/A | $7.5m | Debt | |
N/A | Acquisition | ||
Total Funding | $99.0m |
Recent News about Calypso Medical
EditCalypso Medical is a pioneering company in the field of radiation oncology, specializing in advanced cancer treatment technologies. The company serves radiation oncologists, clinicians, and therapists by providing cutting-edge tools designed to enhance the precision and efficiency of cancer treatments. Operating in the healthcare technology market, Calypso Medical focuses on developing AI-powered systems like Ethos therapy, which personalizes cancer care and completes adaptive treatments within a typical 15-minute timeslot. Their Proton Therapy System offers next-generation proton therapy with ultra-high dose rates and exceptional precision, all within a compact design. The business model revolves around selling these high-tech medical devices and systems to healthcare providers, generating revenue through direct sales, service contracts, and after-sales support. Calypso Medical aims to instill confidence in both healthcare professionals and patients by integrating seamlessly with existing tools and providing comprehensive support resources.
Keywords: AI-powered, cancer care, radiation oncology, adaptive treatment, precision therapy, healthcare technology, proton therapy, medical devices, personalized care, efficient treatment.